Formosa and Rxilient have an exclusive licensing agreement for APP13007 commercialization, including regulatory and sales ...

ViaLase announced the first patient has been treated in its US-based Investigational Device Exemption (IDE) clinical trial ...

Iolyx Therapeutics and Laboratoires Théa (Théa), through support from its subsidiary Théa Open Innovation, have entered into ...

Of the 1000 patients with dry eye symptoms surveyed, 80% stated that “they would try a science-backed eye drop that mimics ...

PainReform has released details on, and the commencement of, its development plan for OcuRing-K, including an upcoming phase 2 clinical trial. 1 ...

Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt ...

The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of ...

The panel reviews the mechanisms, efficacy, and tolerability of novel treatments, including perfluorohexyloctane (Miebo), ...

The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%, which ...

Optogenetics offers mutation-independent vision restoration for IRDs, with promising early-phase results in retinitis ...

The CEO of Dean McGee Eye Institute reflects on the program’s milestones, global partnerships, and the future of ...

Prevent Blindness has declared the first week of December as its 5th annual geographic atrophy (GA) week to educate the ...